S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Forecast, Price & News

$4.46
+0.32 (+7.73%)
(As of 09/22/2023 ET)
Compare
Today's Range
$4.14
$4.48
50-Day Range
$4.14
$5.45
52-Week Range
$3.60
$10.99
Volume
2.71 million shs
Average Volume
3.56 million shs
Market Capitalization
$421.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.63

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
227.9% Upside
$14.63 Price Target
Short Interest
Bearish
16.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to $0.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

333rd out of 963 stocks

Biological Products, Except Diagnostic Industry

51st out of 158 stocks


CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Price History

CHRS Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Analyst Ratings for Coherus BioSciences
10 Analysts Have This to Say About Coherus BioSciences
Coherus Rolls Out YUSIMRY At $995 Per Carton In US
Credit Suisse Remains a Buy on Coherus Biosciences (CHRS)
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
294
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$14.63
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+227.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-291,750,000.00
Net Margins
-145.18%
Pretax Margin
-145.18%

Debt

Sales & Book Value

Annual Sales
$211.04 million
Book Value
($1.77) per share

Miscellaneous

Free Float
84,086,000
Market Cap
$421.34 million
Optionable
Optionable
Beta
0.88

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 68)
    Chairman, Pres & CEO
    Comp: $1.79M
  • Mr. McDavid StilwellMr. McDavid Stilwell (Age 51)
    Chief Financial Officer
    Comp: $719.64k
  • Mr. Bryan J. Mcmichael (Age 45)
    Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Mr. Marek Ciszewski J.D.
    Sr. VP of Investor Relations
  • Mr. Christopher W. Slavinsky (Age 50)
    Chief Bus. & Legal Officer
  • Cheston Turbyfill
    VP of Communications
  • Ms. Rebecca Sunshine (Age 60)
    Chief HR Officer
  • Mr. Michael Chen
    Sr. VP of Commercial Analytics & Trade
  • Mr. Paul Reider (Age 54)
    Chief Commercial Officer













CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2023?

7 equities research analysts have issued twelve-month price objectives for Coherus BioSciences' stock. Their CHRS share price forecasts range from $8.00 to $23.00. On average, they expect the company's stock price to reach $14.63 in the next twelve months. This suggests a possible upside of 227.9% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2023?

Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 43.7% and is now trading at $4.46.
View the best growth stocks for 2023 here
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.17. The biotechnology company had revenue of $58.72 million for the quarter, compared to analyst estimates of $50.83 million.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).

What guidance has Coherus BioSciences issued on next quarter's earnings?

Coherus BioSciences updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00M-, compared to the consensus revenue estimate of $266.16 million.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (16.71%), State Street Corp (2.70%), Aristotle Capital Boston LLC (2.44%), Marshall Wace LLP (2.42%), C WorldWide Group Holding A S (2.39%) and Peregrine Capital Management LLC (1.78%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $4.46.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $421.34 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 294 workers across the globe.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -